Rebound of cystoid macular edema with continued use of acetazolamide in patients with retinitis pigmentosa

Retina. 2007 Oct;27(8):1112-8. doi: 10.1097/IAE.0b013e31805f6b79.


Purpose: To demonstrate the presence of a rebound effect with the use of acetazolamide for the treatment of cystoid macular edema (CME) in patients with retinitis pigmentosa (RP).

Methods: Six patients with RP and cystic-appearing lesions in the macula demonstrated by fluorescein angiography and/or optical coherence tomography (OCT) were treated with an oral form of carbonic anhydrase inhibitor (acetazolamide [500 mg]) as a single daily dose.

Results: All patients, treated with acetazolamide for a period of 3 weeks to 5 weeks, had initial improvement of macular edema demonstrated by OCT. However, extended use of acetazolamide, for at least 8 weeks to 12 weeks, resulted in recurrence (rebound) of CME in 3 of the 6 patients.

Conclusions: Results from our study suggest that rebound of CME with the continued use of acetazolamide observed by OCT may occur more frequently than previously appreciated.

Publication types

  • Case Reports
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetazolamide / adverse effects*
  • Administration, Oral
  • Adult
  • Carbonic Anhydrase Inhibitors / adverse effects*
  • Female
  • Fluorescein Angiography
  • Humans
  • Macular Edema / chemically induced*
  • Macular Edema / drug therapy
  • Macular Edema / physiopathology
  • Male
  • Middle Aged
  • Prospective Studies
  • Recurrence
  • Retinitis Pigmentosa / complications*
  • Tomography, Optical Coherence
  • Visual Acuity


  • Carbonic Anhydrase Inhibitors
  • Acetazolamide